Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yiqi Sanju Decoction (YQSJD) is a Traditional Chinese Medicine (TCM) herbal formula developed by the Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, affiliated with the Shanghai University of Traditional Chinese Medicine. It is specifically formulated to treat metabolic syndrome and its associated components, particularly hypertension and insulin resistance. The decoction's pharmacological profile involves the activation of the SIRT1/AMPK signaling pathway, which enhances energy metabolism and improves glucose and lipid profiles. Additionally, YQSJD has been shown to modulate the gut microbiota composition, reducing systemic inflammation and improving vascular function. Clinical studies have demonstrated its efficacy in reducing blood pressure, waist circumference, and fasting blood glucose levels in patients with metabolic-related disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on yi qi san ju decoction.